Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioids Need Post-Marketing Data To Inform Abuse-Deterrent Claims, FDA Panel Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer’s extended-release opioid Troxyca ER receives advisory committee recommendation for approval and two of three abuse-deterrent labeling claims, but members also want post-marketing data to help make future decisions.

You may also be interested in...



Abuse-Deterrent Opioids: Postmarketing Data Eyed As Development ‘Anchor’

Panelists at US FDA advisory committee on Inspirion's RoxyBond note reservations about abuse-deterrent claims absent more real-world data on how they work; FDA's Staffa suggests agency is eager to see how well premarket work predicts postmarket experience – though the data are far from being available.

Pfizer’s Troxyca And The Limits Of Advisory Committee Review For Opioids

FDA approved Pfizer’s oxycodone/naltrexone extended release opioid with abuse deterrent claims similar to Embeda. That isn’t the label FDA’s advisory committee supported.

Opioid Approval Standards Not Up For Debate, FDA Tells Advisory Cmte.

As Egalet's Arymo ER heads to panel, agency tries to head off discussion about whether it should be approving new opioid products and whether longer clinical efficacy trials should be demanded.

Topics

Related Companies

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel